Psychedelics fast‑track plan

President Donald Trump signed an executive order on April 18 directing federal agencies to speed the review of psychedelic-based treatments for serious mental illness. (whitehouse.gov) The order tells the Food and Drug Administration to give National Priority Vouchers to eligible psychedelic drugs that already have Breakthrough Therapy designation, a status meant to speed development of promising medicines. It also tells the Food and Drug Administration and the Drug Enforcement Administration to create a pathway for some patients to access investigational psychedelic drugs, including ibogaine compounds, under the federal Right to Try law. (whitehouse.gov; fda.gov) The White House said Health and Human Services must put $50 million from the Advanced Research Projects Agency for Health into matching state investments for psychedelic research. The order also directs Health and Human Services, the Food and Drug Administration, the Department of Veterans Affairs, and private companies to increase clinical-trial participation and evidence gathering. (whitehouse.gov) Psychedelics are drugs that can sharply alter perception, mood, and consciousness, and researchers are testing whether supervised use alongside therapy can help patients with post-traumatic stress disorder, depression, addiction, and brain injury. Ibogaine, the compound singled out most often in Saturday’s rollout, is derived from an African shrub and remains illegal in the United States outside research settings. (dea.gov; cbsnews.com) The administration tied the move to veterans’ mental health, an area where federal policy has already started to shift. The Department of Veterans Affairs announced on December 3, 2024 that it would fund its first psychedelic-assisted therapy study since the 1960s, a roughly $1.5 million trial of Methylenedioxymethamphetamine-assisted therapy for veterans with post-traumatic stress disorder and alcohol use disorder. (news.va.gov) Pressure has also been building in Congress. Senators Ruben Gallego of Arizona and David McCormick of Pennsylvania said on March 9 that their bill would require at least five Department of Veterans Affairs centers of excellence to study treatments including Methylenedioxymethamphetamine, ibogaine, ketamine, and psilocybin for veterans. (gallego.senate.gov) The push comes amid stubborn mental-health numbers. A July 2025 Government Accountability Office report said about 14.6 million U.S. adults had a serious mental illness in 2023, and the Department of Veterans Affairs’ 2024 suicide report said veterans died by suicide at an average rate of 17.6 per day in 2022. (gao.gov; mentalhealth.va.gov) The legal barrier is still high. The Drug Enforcement Administration says Schedule I drugs are defined as having no currently accepted medical use and a high potential for abuse, and its examples include lysergic acid diethylamide, peyote, and 3,4-methylenedioxymethamphetamine; the White House order says the attorney general should review rescheduling after successful Phase 3 trials and Food and Drug Administration approval. (dea.gov; whitehouse.gov) The administration is moving faster than the science has settled. CBS News reported that ibogaine evidence still rests largely on small studies and one completed double-blind, placebo-controlled randomized trial, even as officials said federal decisions on some psychedelic drugs could come as soon as summer 2026. (cbsnews.com; usnews.com) For now, the order does not approve any new psychedelic treatment. It changes the federal queue, adds money, and tells regulators to prepare for drugs that are still in trials. (whitehouse.gov)